- Home
- BCTX vs WVVI Comparison
BCTX vs WVVI Comparison
Compare BCTX & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- WVVI
- Stock Information
- Founded
- BCTX 2014
- WVVI 1983
- Country
- BCTX Canada
- WVVI United States
- Employees
- BCTX N/A
- WVVI N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- WVVI Beverages (Production/Distribution)
- Sector
- BCTX Health Care
- WVVI Consumer Staples
- Exchange
- BCTX Nasdaq
- WVVI Nasdaq
- Market Cap
- BCTX 17.2M
- WVVI 16.5M
- IPO Year
- BCTX N/A
- WVVI N/A
- Fundamental
- Price
- BCTX $0.79
- WVVI $3.36
- Analyst Decision
- BCTX Strong Buy
- WVVI
- Analyst Count
- BCTX 1
- WVVI 0
- Target Price
- BCTX $15.00
- WVVI N/A
- AVG Volume (30 Days)
- BCTX 690.7K
- WVVI 7.7K
- Earning Date
- BCTX 12-12-2024
- WVVI 11-12-2024
- Dividend Yield
- BCTX N/A
- WVVI N/A
- EPS Growth
- BCTX N/A
- WVVI N/A
- EPS
- BCTX N/A
- WVVI N/A
- Revenue
- BCTX N/A
- WVVI $39,259,016.00
- Revenue This Year
- BCTX N/A
- WVVI N/A
- Revenue Next Year
- BCTX N/A
- WVVI N/A
- P/E Ratio
- BCTX N/A
- WVVI N/A
- Revenue Growth
- BCTX N/A
- WVVI N/A
- 52 Week Low
- BCTX $0.46
- WVVI $3.26
- 52 Week High
- BCTX $5.97
- WVVI $5.44
- Technical
- Relative Strength Index (RSI)
- BCTX 55.70
- WVVI 46.96
- Support Level
- BCTX $0.57
- WVVI $3.32
- Resistance Level
- BCTX $0.74
- WVVI $3.40
- Average True Range (ATR)
- BCTX 0.06
- WVVI 0.11
- MACD
- BCTX 0.00
- WVVI -0.00
- Stochastic Oscillator
- BCTX 88.08
- WVVI 29.71
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About WVVI Willamette Valley Vineyards Inc.
Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.